Generic placeholder image

Current Diabetes Reviews

Editor-in-Chief

ISSN (Print): 1573-3998
ISSN (Online): 1875-6417

Review Article

Cardiovascular Disease among Patients with Diabetes: The Current Scenario in Saudi Arabia

Author(s): Asirvatham Alwin Robert* and Mohamed Abdulaziz Al Dawish

Volume 17, Issue 2, 2021

Published on: 27 May, 2020

Page: [180 - 185] Pages: 6

DOI: 10.2174/1573399816666200527135512

Price: $65

Abstract

One of the well-recognized conditions linked to diabetes mellitus (DM) is cardiovascular disease (CVD). Those affected by DM face greater risk for early onset of CVD. Although huge strides have been made in cardiovascular therapy and prevention, with striking results in decreasing diabetesrelated coronary mortality in developed countries, the morbidity and mortality due to CVD continue to remain high among patients with diabetes. While there is an increasing incidence of cardiovascular event survivors with DM across the world, the number of DM patients with higher cardiovascular risk is predicted to soar, presenting a massive challenge for health care systems globally, including Saudi Arabia. A report of the Saudi Scientific Diabetes Society indicates that more than 50% of patients with DM die due to cardiovascular causes. In fact, Saudi Arabia globally ranks among the top 10 countries in the prevalence of diabetes. However, the incidence of CVD and its risk factors among patients with diabetes in Saudi Arabia have not yet been well documented. This review aims to present an overview of CVD among patients with DM in Saudi Arabia, through a comprehensive review of currently available published literature. The findings indicate that diabetes linked CVD burden in Saudi Arabia is expected to exponentially increase to a very high degree unless a wide-ranging epidemic control program is initiated. The findings emphasize the need for maintenance of a healthy diet accompanied by exercise, an active lifestyle and weight control measures among the population. It is essential that the health care system focus on raising awareness among the population, and implement appropriate measures for prevention, early detection and suitable management of CVD among patients with DM.

Keywords: Diabetes complication, vascular diseases, type 2 diabetes, macrovascular complications, cardiovascular disease, awareness, noncommunicable diseases, Saudi Arabia.

[1]
M Alquaiz A R Siddiqui A, H Qureshi R, et al.. Women Health in Saudi Arabia: A review of non-communicable diseases and their risk factors. Pak J Med Sci 2014; 30(2): 422-31.
[PMID: 24772156]
[2]
Al Dawish MA, Robert AA, Braham R, et al. Diabetes Mellitus in Saudi Arabia: A Review of the Recent Literature. Curr Diabetes Rev 2016; 12(4): 359-68.
[http://dx.doi.org/10.2174/1573399811666150724095130] [PMID: 26206092]
[3]
Beran D, Pedersen HB, Robertson J. Noncommunicable diseases, access to essential medicines and universal health coverage. Glob Health Action 2019; 12(1)1670014
[http://dx.doi.org/10.1080/16549716.2019.1670014] [PMID: 31573421]
[4]
Soenarta AA, Buranakitjaroen P, Chia YC, et al. An overview of hypertension and cardiac involvement in Asia: Focus on heart failure. J Clin Hypertens (Greenwich) 2020; 22(3): 423-30.
[http://dx.doi.org/10.1111/jch.13753] [PMID: 31955506]
[5]
World Health Organization. 2016.Noncommunicable diseases https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases
[6]
Huang D, Refaat M, Mohammedi K, Jayyousi A, Al Suwaidi J, Abi Khalil C. Macrovascular Complications in Patients with Diabetes and Prediabetes. BioMed Res Int 2017.20177839101
[http://dx.doi.org/10.1155/2017/7839101] [PMID: 29238721]
[7]
Strain WD, Paldánius PM. Diabetes, cardiovascular disease and the microcirculation. Cardiovasc Diabetol 2018; 17(1): 57.
[http://dx.doi.org/10.1186/s12933-018-0703-2] [PMID: 29669543]
[8]
World Health Organization - Noncommunicable Diseases (NCD) Country Profiles. 2018.https://www.who.int/nmh/countries/sau_en.pdf
[9]
Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339(4): 229-34.
[http://dx.doi.org/10.1056/NEJM199807233390404] [PMID: 9673301]
[10]
Balakumar P, Maung UK, Jagadeesh G. Prevalence and prevention of cardiovascular disease and diabetes mellitus. Pharmacol Res 2016; 113: 600-9.
[http://dx.doi.org/10.1016/j.phrs.2016.09.040]
[11]
Abraham TM, Pencina KM, Pencina MJ, Fox CS. Trends in diabetes incidence: the Framingham Heart Study. Diabetes Care 2015; 38(3): 482-7.
[http://dx.doi.org/10.2337/dc14-1432] [PMID: 25552418]
[12]
International Diabetes Federation. Diabetes and cardiovascular disease. Brussels: International Diabetes Federation 2016; pp. 1-144.
[13]
Giorgino F, Leonardini A, Laviola L. Cardiovascular disease and glycemic control in type 2 diabetes: now that the dust is settling from large clinical trials. Ann N Y Acad Sci 2013; 1281: 36-50.
[http://dx.doi.org/10.1111/nyas.12044] [PMID: 23387439]
[14]
Rangel EB, Rodrigues CO, de Sá JR. Micro- and Macrovascular Complications in Diabetes Mellitus: Preclinical and Clinical Studies. J Diabetes Res 2019.20192161085
[http://dx.doi.org/10.1155/2019/2161085] [PMID: 30911551]
[15]
Leon BM, Maddox TM. Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research. World J Diabetes 2015; 6(13): 1246-58.
[http://dx.doi.org/10.4239/wjd.v6.i13.1246] [PMID: 26468341]
[16]
Szuszkiewicz-Garcia MM, Davidson JA. Cardiovascular disease in diabetes mellitus: risk factors and medical therapy. Endocrinol Metab Clin North Am 2014; 43(1): 25-40.
[http://dx.doi.org/10.1016/j.ecl.2013.09.001] [PMID: 24582090]
[17]
Singh GM, Danaei G, Farzadfar F, et al. Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group. Asia-Pacific Cohort Studies Collaboration (APCSC); Diabetes Epidemiology: Collaborative analysis of Diagnostic criteria in Europe (DECODE); Emerging Risk Factor Collaboration (ERFC); Prospective Studies Collaboration (PSC). The age-specific quantitative effects of metabolic risk factors on cardiovascular diseases and diabetes: a pooled analysis. PLoS One 2013; 8(7)e65174
[http://dx.doi.org/10.1371/journal.pone.0065174] [PMID: 23935815]
[18]
King RJ, Grant PJ. Diabetes and cardiovascular disease: pathophysiology of a life-threatening epidemic. Herz 2016; 41(3): 184-92.
[http://dx.doi.org/10.1007/s00059-016-4414-8] [PMID: 27026400]
[19]
Beckman JA, Creager MA. Vascular Complications of Diabetes. Circ Res 2016; 118(11): 1771-85.
[http://dx.doi.org/10.1161/CIRCRESAHA.115.306884] [PMID: 27230641]
[20]
International Diabetes Federation Middle East & North Africa. 2017.https://idf.org/our-network/regions-members/middle-east-and-north-africa/members/46-saudi-arabia.html
[22]
[23]
Ahmed AM, Hersi A, Mashhoud W, et al. Cardiovascular risk factors burden in Saudi Arabia: The Africa Middle East Cardiovascular Epidemiological (ACE) study. J Saudi Heart Assoc 2017; 29(4): 235-43.
[http://dx.doi.org/10.1016/j.jsha.2017.03.004] [PMID: 28983166]
[24]
Ghamri RA, Alzahrani NS, Alharthi AM, Gadah HJ, Badoghaish BG, Alzahrani AA. Cardiovascular risk factors among high-risk individuals attending the general practice at king Abdulaziz University hospital: a cross-sectional study. BMC Cardiovasc Disord 2019; 19(1): 268.
[http://dx.doi.org/10.1186/s12872-019-1261-6] [PMID: 31775642]
[25]
Public Health Resource Unit. Critical Appraisal Skills,. 1998.http://www.york.ac.uk/inst/crd/
[26]
Mohammed ME, Al-Raddadi RM, Alhaeli AM, et al. Cardiovascular Disease Risk Assessment among Saudi Type 2 Diabetic Patients in Jeddah City, Saudi Arabia. Imperial Journal of Interdisciplinary Research 2017; 3(11): 100-7.
[27]
Aljefree N, Ahmed F. Prevalence of cardiovascular disease and associated risk factors among adult population in the gulf region: a systematic review. Adv Public Health 2015; 2015: 1-23.
[http://dx.doi.org/10.1155/2015/235101]
[28]
Kokubo Y, Matsumoto C. Hypertension Is a Risk Factor for Several Types of Heart Disease: Review of Prospective Studies. Adv Exp Med Biol 2017; 956: 419-26.
[http://dx.doi.org/10.1007/5584_2016_99] [PMID: 27815926]
[29]
Joseph JJ, Golden SH. Type 2 diabetes and cardiovascular disease: what next? Curr Opin Endocrinol Diabetes Obes 2014; 21(2): 109-20.
[http://dx.doi.org/10.1097/MED.0000000000000044] [PMID: 24569552]
[30]
Fox CS, Sullivan L, D’Agostino RB Sr, Wilson PW. Framingham Heart Study. The significant effect of diabetes duration on coronary heart disease mortality: the Framingham Heart Study. Diabetes Care 2004; 27(3): 704-8.
[http://dx.doi.org/10.2337/diacare.27.3.704] [PMID: 14988289]
[31]
Matheus AS, Tannus LR, Cobas RA, Palma CC, Negrato CA, Gomes MB. Impact of diabetes on cardiovascular disease: an update. Int J Hypertens 2013.2013653789
[http://dx.doi.org/10.1155/2013/653789] [PMID: 23533715]
[32]
Ahmed AA, Alsharief E, Alsharief A. Evaluation of risk factors for cardiovascular diseases among Saudi diabetic patients attending primary health care service. Diabetes Metab Syndr 2013; 7(3): 133-7.
[http://dx.doi.org/10.1016/j.dsx.2013.06.012] [PMID: 23953177]
[33]
Kelly TN, Bazzano LA, Fonseca VA, Thethi TK, Reynolds K, He J. Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med 2009; 151(6): 394-403.
[http://dx.doi.org/10.7326/0003-4819-151-6-200909150-00137] [PMID: 19620144]
[34]
Kim M, Oh JK, Sakata S, et al. Role of resistin in cardiac contractility and hypertrophy. J Mol Cell Cardiol 2008; 45(2): 270-80.
[http://dx.doi.org/10.1016/j.yjmcc.2008.05.006] [PMID: 18597775]
[35]
Athyros VG, Doumas M, Imprialos KP, et al. Diabetes and lipid metabolism. Hormones (Athens) 2018; 17(1): 61-7.
[http://dx.doi.org/10.1007/s42000-018-0014-8] [PMID: 29858856]
[36]
Al-Baghli NA, Al-Ghamdi AJ, Al-Turki KA, et al. Awareness of cardiovascular disease in eastern Saudi Arabia. J Family Community Med 2010; 17(1): 15-21.
[http://dx.doi.org/10.4103/1319-1683.68784] [PMID: 22022666]
[37]
Chang SA. Smoking and type 2 diabetes mellitus. Diabetes Metab J 2012; 36(6): 399-403.
[http://dx.doi.org/10.4093/dmj.2012.36.6.399] [PMID: 23275932]
[38]
Ko SH, Kim SR, Kim DJ, et al. Committee of Clinical Practice Guidelines, Korean Diabetes Association. 2011 clinical practice guidelines for type 2 diabetes in Korea. Diabetes Metab J 2011; 35(5): 431-6.
[http://dx.doi.org/10.4093/dmj.2011.35.5.431] [PMID: 22111032]
[39]
Alharbi SH. Risk of Cardiovascular Disease among Saudi Diabetic Patients. Saudi J Med 2018; 3(1): 26-31.
[40]
Al Slail FY, Abid O, Assiri AM, Memish ZA, Ali MK. Cardiovascular risk profiles of adults with type-2 diabetes treated at urban hospitals in Riyadh, Saudi Arabia. J Epidemiol Glob Health 2016; 6(1): 29-36.
[http://dx.doi.org/10.1016/j.jegh.2015.07.004] [PMID: 26257035]
[41]
Rahman Al-Nuaim A. High prevalence of metabolic risk factors for cardiovascular diseases among Saudi population, aged 30-64 years. Int J Cardiol 1997; 62(3): 227-35.
[http://dx.doi.org/10.1016/S0167-5273(97)00268-4] [PMID: 9476683]
[42]
Osman AK, al-Nozha MM. Risk factors of coronary artery disease in different regions of Saudi Arabia. East Mediterr Health J 2000; 6(2-3): 465-74.
[PMID: 11556038]
[43]
Elhadd TA, Al-Amoudi AA, Alzahrani AS. Epidemiology, clinical and complications profile of diabetes in Saudi Arabia: a review. Ann Saudi Med 2007; 27(4): 241-50.
[PMID: 17684435]
[44]
Al-Humaidi MA. Probability of coronary artery disease among patients attending primary health care centers (PHCCs) in Southwest Saudi Arabia. Ethn Dis 2000; 10(3): 350-6.
[PMID: 11110351]
[45]
Soofi MA, Youssef MA. Prediction of 10-year risk of hard coronary events among Saudi adults based on prevalence of heart disease risk factors. J Saudi Heart Assoc 2015; 27(3): 152-9.
[http://dx.doi.org/10.1016/j.jsha.2015.03.003] [PMID: 26136629]
[46]
Einarson TR, Acs A, Ludwig C, Panton UH. Economic Burden of Cardiovascular Disease in Type 2 Diabetes: A Systematic Review. Value Health 2018; 21(7): 881-90.
[http://dx.doi.org/10.1016/j.jval.2017.12.019] [PMID: 30005761]
[47]
he Investment Case for Noncommunicable Disease Prevention and Control in the Kingdom of Saudi Arabia, World Health Organization 2018.
[48]
Mokdad AH, Tuffaha M, Hanlon M, et al. Z.; Basulaiman, M.; AlMazroa, M.A.; Al Rabeeah, A.A. Cost of Diabetes in the Kingdom of Saudi Arabia, 2014. J Diabetes Metab 2015; 6: 575.
[http://dx.doi.org/10.4172/2155-6156.1000575]
[49]
Robert AA, Al Dawish MA. The Worrying Trend of Diabetes Mellitus in Saudi Arabia: An Urgent Call to Action. Curr Diabetes Rev 2020; 16(3): 204-10.
[http://dx.doi.org/10.2174/1573399815666190531093735] [PMID: 31146665]
[50]
Ellahham S. Diabetes and its associated cardiovascular complications in the Arabian Gulf: Challenges and Opportunities. J Clin Exp Cardiolog 2020; 11: 650.
[http://dx.doi.org/10.4172/2329-6607.1000650]
[52]
International Diabetes Federation. IDF Diabetes Atlas. 8th ed. Brussels, Belgium 2017.
[53]
Almalki MA, AlJishi MN, Khayat MA, et al. Population awareness of coronary artery disease risk factors in Jeddah, Saudi Arabia: a cross-sectional study. Int J Gen Med 2019; 12: 63-70.
[http://dx.doi.org/10.2147/IJGM.S184732] [PMID: 30666149]
[54]
Simmons RK, Griffin SJ, Lauritzen T, Sandbæk A. Effect of screening for type 2 diabetes on risk of cardiovascular disease and mortality: a controlled trial among 139,075 individuals diagnosed with diabetes in Denmark between 2001 and 2009. Diabetologia 2017; 60(11): 2192-9.
[http://dx.doi.org/10.1007/s00125-017-4299-y] [PMID: 28831539]
[55]
Mohammedi K, Woodward M, Marre M, et al. Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes. Cardiovasc Diabetol 2017; 16(1): 95.
[http://dx.doi.org/10.1186/s12933-017-0574-y] [PMID: 28750645]
[56]
Cannon CP, Braunwald E, McCabe CH, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350(15): 1495-504.
[http://dx.doi.org/10.1056/NEJMoa040583] [PMID: 15007110]
[57]
Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. Cardiovasc Diabetology 2018; 17(1): 83.
[58]
Nathan DM, Cleary PA, Backlund JY, et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353(25): 2643-53.
[http://dx.doi.org/10.1056/NEJMoa052187] [PMID: 16371630]
[59]
Nathan DM, Genuth S, Lachin J, et al. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329(14): 977-86.
[http://dx.doi.org/10.1056/NEJM199309303291401] [PMID: 8366922]
[60]
Gerstein HC, Miller ME, Byington RP, et al. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358(24): 2545-59.
[http://dx.doi.org/10.1056/NEJMoa0802743] [PMID: 18539917]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy